Accounts Payable and Accrued Expenses, and Related Party (Tables)

6 Months Ended

Jun. 30, 2024

Accounts payable consists of the following:

Schedule of Accounts Payable

	As of June 30, 2024		As of December 31, 2023
		(Unaudited)
Accounts payable to Cytovance, a related party ¹	$	842,000	$	3,515,000
Other accounts payable		875,000		813,000
Total accounts payable	$	1,717,000	$	4,328,000

Accrued Expenses consists of the following:

Schedule of Accrued Expenses

	As of June 30, 2024		As of December 31, 2023
		(Unaudited)
Accrued expenses, University of Minnesota	$	862,000	$	192,000
Other accrued expenses		903,000		1,003,000
Total accrued expenses	$	1,765,000	$	1,195,000

The details of the Company’s accounts payable to Cytovance Biologics, Inc., were as follows:

	June 30, 2024			June 30, 2023
	Six Months Ending
	June 30, 2024			June 30, 2023
	(Unaudited)			(Unaudited)
Beginning balance	$	3,515,000		$	2,283,000
Invoices, net		778,000			2,877,000
Payments in cash		(2,641,000	)		(1,130,000	)
Payments in common stock, at fair value		(810,000	)		(1,120,000	)
Ending balance	$	842,000		$	2,910,000